Sensei Biotherapeutics, Inc.
NASDAQ: SNSE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher W. Gerry
- Employees
- 14
- Headquarters
- Rockville, United States
- IPO year
- 2021
- Market cap
- $18.6M
- Website
- https://www.senseibio.com
Loading SNSE…
Loading profile data…Frequently asked questions about SNSE
What does Sensei Biotherapeutics, Inc. (SNSE) do?
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune respon...
Where does SNSE trade?
Sensei Biotherapeutics, Inc. (SNSE) trades on the NASDAQ Global Market.
What sector is SNSE in?
Sensei Biotherapeutics, Inc. (SNSE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sensei Biotherapeutics, Inc.?
Christopher W. Gerry is the chief executive officer of Sensei Biotherapeutics, Inc. (SNSE).
Where is Sensei Biotherapeutics, Inc. headquartered?
Sensei Biotherapeutics, Inc. is headquartered in United States.
Does SNSE pay a dividend?
Sensei Biotherapeutics, Inc. (SNSE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SNSE go public?
Sensei Biotherapeutics, Inc. (SNSE) completed its initial public offering in 2021.